AstraZeneca Exchange Cambridge

A Changing World: Future Trends in the Global Biopharmaceuticals Market

On Monday, 26 June 2017, we hosted a global life science networking event – AstraZeneca Exchange Cambridge – in Cambridge, UK, one of our three strategic R&D hubs.


It’s an opportunity to bring people together from all kinds of different disciplines and perspectives in business, academia and science to talk about what’s happening in the world - to talk about how we can bring science and medicines to more people.

Mark Mallon Executive Vice-President, Global Product Portfolio Strategy, AstraZeneca

The event brought together senior representatives from across the life science sector, covering industry, biotech, academia, Government and the public sector. It was an opportunity for high-level discussion about the future challenges and opportunities facing the industry globally, in a changing political, economic and social environment, with a particular focus on Europe and China. 


Andrew Marr, Presenter and ex-BBC Political Editor, opening the event


The event was opened by Andrew Marr, Presenter and ex-BBC Political Editor, giving an overview of the current political environment in the UK and his thoughts on the Brexit negotiations. It then featured a combination of keynote presentations, panel discussions and Q&As with other high-profile speakers including:


  • Minister Counsellor Jin Xu, Economic and Commercial Counsellor’s Office, UK Embassy of the People's Republic of China
  • Sir Harpal Kumar, CEO, Cancer Research UK
  • Kevin Holland, Minister-Counsellor and Director of Life Sciences, Healthcare and Social Care, China, British Embassy, Beijing
  • Nicole Mather, Director, UK Office for Life Sciences
  • Chris Cotton, Director, China-Britain Business Council
  • Dr Hamish Cameron, Operating Partner, SV Health Investors
  • Dr Ian Campbell, Director, Health and Life Sciences, Innovate UK
  • Mark Mallon, Executive Vice-President, Global Product Portfolio Strategy, AstraZeneca
  • Mene Pangalos, Executive Vice-President, IMED Biotech Unit and Business Development, AstraZeneca


(l-r) Jane Osbourn, Site Leader and Vice-President, R&D, MedImmune and Chair of the BIA, moderating a panel discussion with Dr Hamish Cameron, SV Health Investors, Sir Harpal Kumar, Cancer Research UK, Nicole Mather, UK Office for Life Sciences, and Dr Ian Campbell, Innovate UK


Guests networking during the AstraZeneca Exchange Cambridge 2017 event


It’s hugely important for AstraZeneca and MedImmune to be hosting an event with our colleagues and collaborators from across the Cambridge ecosystem and science community. I think it gives us an opportunity to deepen and broaden the relationships that we’ve formed over the last two or three years.

Shaun Grady Vice-President, Business Development Operations, AstraZeneca